Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 14/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | NSD2 | O96028 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30209214 | 0.87 | ROCK1 (0.48) | TRPV1KMT2AMEN1MAPK1HTT | |
| SCHEMBL1277271 | 0.85 | TRPV1 (0.52) | TRPV1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL1312094 | 0.84 | TRPV1 (0.74) | TRPV1KMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL4028212 | 0.83 | TRPV1 (0.65) | TRPV1KMT2AMEN1MAPK1HTT | |
| SCHEMBL30114438 | 0.81 | TRPV1 (0.64) | TRPV1KMT2AMEN1MAPK1HTT | |
| SCHEMBL4023786 | 0.81 | TRPV1 (0.64) | TRPV1KMT2AMEN1MAPK1HTT | |
| SCHEMBL2315592 | 0.80 | KDM4E (0.67) | TRPV1KMT2AMEN1MAPK1HTT | |
| SCHEMBL30544195 | 0.80 | KDM4E (0.67) | TRPV1KMT2AMEN1MAPK1HTT | |
| SCHEMBL5660097 | 0.79 | TRPV1 (0.71) | TRPV1 | |
| SCHEMBL8154848 | 0.79 | TRPV1 (0.66) | TRPV1KMT2AMEN1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010023512-A1 | NOVEL VANILLOID RECEPTOR MODULATORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MATRIX LABORATORIES LTD. (IN) | 2010-03-04 | — | — | WO | claimed |
| EP-4257192-A2 | ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATEMTN OF OPHTHALMIC DISORDERS | Industrial Technology Research Institute (TW) | 2023-10-11 | — | — | EP | disclosed |
| EP-3505513-B1 | ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATEMTN OF OPHTHALMIC DISORDERS | IND TECH RES INST (TW) | 2023-09-27 | — | — | EP | disclosed |
| CN-109956900-B | Compounds and pharmaceutical compositions comprising the same | 财团法人工业技术研究院 | 2023-02-03 | — | — | CN | disclosed |
| US-10696638-B2 | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2020-06-30 | — | — | US | disclosed |
| CN-107108593-B | Substituted oxazole and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands II | 美迪福伦DBT有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-3505513-A1 | ISOQUINOLINE DERIVATIVES AND THEIR USE FOR THE TREATEMTN OF OPHTHALMIC DISORDERS | Industrial Technology Research Institute (TW) | 2019-07-03 | — | — | EP | disclosed |
| US-20190194137-A1 | COMPOUNDS FOR INHIBITING AGC KINASE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2019-06-27 | — | — | US | disclosed |
| EP-3224252-B1 | SUBSTITUTED OXAZOLE- AND THIAZOLE-BASED CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS II | MEDIFRON DBT INC (KR) | 2019-01-09 | — | — | EP | disclosed |
| US-9771359-B1 | Substituted oxazole- and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands II | MEDIFRON DBT INC. (KR) | 2017-09-26 | — | — | US | disclosed |
| US-20080097102-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | CODD ELLEN | 2008-04-24 | — | — | US | disclosed |
| WO-2008010061-A2 | 3-AZABICYCLO [3.1.0] HEXANE VANILLOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007042906-A1 | SUBSTITUTED BENZOFUSED DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS | GLENMARK PHARMACEUTICALS S.A. (US) | 2007-04-19 | — | — | WO | disclosed |
| US-20060270693-A1 | Ether derivative | AJINOMOTO CO., INC. (JP) | 2006-11-30 | — | — | US | disclosed |
| EP-1679296-A1 | ETHER DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2006-07-12 | — | — | EP | disclosed |
| US-6984647-B2 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-01-10 | — | — | US | disclosed |
| US-20050187291-A1 | use of 2-(urea or thiourea)tetralins as analgesic or to treat pulmonary dysfunction | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-08-25 | — | — | US | disclosed |
| EP-1506166-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | disclosed |
| US-20030236280-A1 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-12-25 | — | — | US | disclosed |
| WO-2003097586-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097102-A1 | AMINOTETRALIN-DERIVED UREA MODULATORS OF VANILLOID VR1 RECEPTOR | UTS2R, TRPV1, GPR17 | TRPV1 2/4885KMT2A 4174/4885MEN1 4715/4885 |
| US-20060270693-A1 | Ether derivative | UROD, IL5, IL17A | TRPV1 30/4885KMT2A 648/4885MEN1 4235/4885 |
| US-20190194137-A1 | COMPOUNDS FOR INHIBITING AGC KINASE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | GRK4, NCOA4, GRK3 | TRPV1 2478/4885KMT2A 1680/4885MEN1 4432/4885 |
| US-20050187291-A1 | use of 2-(urea or thiourea)tetralins as analgesic or to treat pulmonary dysfunction | TMEM109, UTS2R, GPR17 | TRPV1 10/4885KMT2A 4468/4885MEN1 4484/4885 |
| US-10696638-B2 | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same | GRK4, NCOA4, GRK3 | TRPV1 2478/4885KMT2A 1680/4885MEN1 4432/4885 |
| US-20030236280-A1 | Aminotetralin-derived urea modulators of vanilloid VR1 receptor | UTS2R, TRPV6, TRPV1 | TRPV1 3/4885KMT2A 4051/4885MEN1 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.